Literature DB >> 16098417

Revascularization in severe left ventricular dysfunction: the role of viability testing.

Panithaya Chareonthaitawee1, Bernard J Gersh, Philip A Araoz, Raymond J Gibbons.   

Abstract

Revascularization is a treatment option for moderate-to-severe ischemic cardiomyopathy. Limitations of the current literature, lack of completed randomized trials, and higher periprocedural risks create significant uncertainty about the optimal treatment strategy. This review focuses on the available literature describing the effect of revascularization on outcome and the role of noninvasive viability testing. It attempts to identify a subset of patients likely to benefit from therapy.

Entities:  

Mesh:

Year:  2005        PMID: 16098417     DOI: 10.1016/j.jacc.2005.03.072

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  30 in total

1.  Impact of CT attenuation correction on the viability pattern assessed by 99mTc-tetrofosmin SPECT/ 18F-FDG PET.

Authors:  Rene Nkoulou; Aju P Pazhenkottil; Ronny R Buechel; Lars Husmann; Ines Valenta; Bernhard A Herzog; Mathias Wolfrum; Jelena R Ghadri; Philipp A Kaufmann
Journal:  Int J Cardiovasc Imaging       Date:  2010-10-08       Impact factor: 2.357

2.  Prediction of long-term reverse left ventricular remodeling after revascularization or medical treatment in patients with ischemic cardiomyopathy: a comparative study between SPECT and MRI.

Authors:  Tomas Skala; Martin Hutyra; Jan Vaclavik; Milan Kaminek; David Horak; Josef Novotny; Jana Zapletalova; Jan Lukl; Dan Marek; Milos Taborsky
Journal:  Int J Cardiovasc Imaging       Date:  2010-08-20       Impact factor: 2.357

3.  Assessment of myocardial viability: more than measurements of radiotracer uptake alone.

Authors:  James A Arrighi
Journal:  J Nucl Cardiol       Date:  2006 Mar-Apr       Impact factor: 5.952

4.  Thirty-four years of hibernating myocardium: a case report.

Authors:  Erik Wissner; Farouk Mookadam
Journal:  J Nucl Cardiol       Date:  2007 Sep-Oct       Impact factor: 5.952

5.  Mid-term results of coronary bypass graft surgery in patients with ischaemic left ventricular systolic dysfunction and no detected myocardial viability.

Authors:  Jun Liu; Zixiong Liu; Anqing Chen; Zhe Wang; Mi Zhou; Junfeng Cai; Qiang Zhao
Journal:  Interact Cardiovasc Thorac Surg       Date:  2016-02-23

6.  Prayer and reverence in naturalistic, aesthetic, and socio-moral contexts predicted fewer complications following coronary artery bypass.

Authors:  Amy L Ai; Paul Wink; Terrence N Tice; Steven F Bolling; Marshall Shearer
Journal:  J Behav Med       Date:  2009-10-25

Review 7.  Korean Guidelines for Diagnosis and Management of Chronic Heart Failure.

Authors:  Min-Seok Kim; Ju-Hee Lee; Eung Ju Kim; Dae-Gyun Park; Sung-Ji Park; Jin Joo Park; Mi-Seung Shin; Byung Su Yoo; Jong-Chan Youn; Sang Eun Lee; Sang Hyun Ihm; Se Yong Jang; Sang-Ho Jo; Jae Yeong Cho; Hyun-Jai Cho; Seonghoon Choi; Jin-Oh Choi; Seong Woo Han; Kyung Kuk Hwang; Eun Seok Jeon; Myeong-Chan Cho; Shung Chull Chae; Dong-Ju Choi
Journal:  Korean Circ J       Date:  2017-09-18       Impact factor: 3.243

8.  Left ventricular dyssynchrony assessment by phase analysis from gated PET-FDG scans.

Authors:  Aju P Pazhenkottil; Ronny R Buechel; Rene Nkoulou; Jelena-Rima Ghadri; Bernhard A Herzog; Lars Husmann; Mathias Wolfrum; Silke M Küest; Michael Fiechter; Oliver Gaemperli; Philipp A Kaufmann
Journal:  J Nucl Cardiol       Date:  2011-06-14       Impact factor: 5.952

9.  Does imaging-guided selection of patients with ischemic heart failure for high risk revascularization improve identification of those with the highest clinical benefit?: Myocardial imaging should not exclude patients with ischemic heart failure from coronary revascularization.

Authors:  Eric J Velazquez
Journal:  Circ Cardiovasc Imaging       Date:  2012-03       Impact factor: 7.792

Review 10.  Integrated imaging of cardiac anatomy, physiology, and viability.

Authors:  James A Arrighi
Journal:  Curr Cardiol Rep       Date:  2009-03       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.